Companies Reporting Before The Bell
• AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Mizuho Securities says that the Satsuma Pharmaceuticals Inc (NASDAQ: STSA) story is essentially unchanged. It remains bullish on STS101's potential as an effective, safe, and reliable intranasal dihydroergotamine (DHE) for migraine.
Impel NeuroPharma (NASDAQ:IMPL) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement.
Analysts estimate that Impel NeuroPharma will report an earnings per share (EPS) of $-1.05.
Impel NeuroPharma (NASDAQ:IMPL) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(0.87) by 22.99 percent. The company reported quarterly sales of $577.00 thousand which
-Transaction Provides Immediate, Non-Dilutive Capital to Further Support Commercialization of Trudhesa™
-$100 million in gross proceeds to be funded at close, extending estimated corporate cash runway into 2024
Benzinga’s “After-Hours Movers & News” highlights the biggest movers of the day. The information on the price action is collected using Benzinga Pro's Movers tool.
Benzinga Pro users can cross-reference the Movers tool with the Benzinga Pro News tool to identify potential news catalysts moving stocks.